risedronic acid has been researched along with Osteoporotic Fractures in 60 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Osteoporotic Fractures: Breaks in bones resulting from low bone mass and microarchitectural deterioration characteristic of OSTEOPOROSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC)." | 7.78 | Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. ( Basso, U; Berton, L; Brunello, A; Coin, A; Falci, C; Manzato, E; Monfardini, S; Perissinotto, E; Pintore, G; Sergi, G; Veronese, N, 2012) |
| "Retrospective single-center cohort study of osteoporosis patients treated with alendronate or risedronate for at least 2 years and then discontinued their bisphosphonate for a drug holiday." | 3.83 | Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday. ( Adams-Huet, B; Maalouf, NM; Poindexter, JR; Xu, LH, 2016) |
| " Assuming a willingness to pay (WTP) of €32,000 per quality-adjusted life years (QALYs), treatment with generic alendronate is cost effective for men and women aged 50 years or more, with 10-year probabilities for major osteoporotic fractures and hip above 8." | 3.83 | Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal. ( Borgström, F; da Silva, JA; Kanis, JA; Lourenço, Ó; Marques, A; Ortsäter, G, 2016) |
| "Little is known of the effect of alendronate and risedronate on osteoporotic fractures after discontinuation of therapy." | 3.81 | Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA). ( Garellick, G; Landfeldt, E; Ström, O, 2015) |
| " Alendronate, risedronate, zoledronate and denosumab have been shown to prevent spine, nonspine and hip fractures; in addition, teriparatide and strontium ranelate prevent both spine and nonspine fractures, and raloxifene and ibandronate prevent spine fractures." | 3.81 | Efficacy, effectiveness and side effects of medications used to prevent fractures. ( Reid, IR, 2015) |
| "The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC)." | 3.78 | Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. ( Basso, U; Berton, L; Brunello, A; Coin, A; Falci, C; Manzato, E; Monfardini, S; Perissinotto, E; Pintore, G; Sergi, G; Veronese, N, 2012) |
| " Medicines dispensed at a pharmacy which are indicated for the prevention of osteoporotic hip fractures (alendronate, risedronate and strontium ranelate)." | 3.77 | [Incidence of hip fractures due to osteoporosis in relation to the prescription of drugs for their prevention and treatment in Galicia, Spain]. ( Charle-Crespo, MÁ; Gomes-Carvalho, CS; Guerra-García, MM; Prejigueiro-Santás, A; Puga-Sarmiento, E; Rodríguez-Fernández, JB, 2011) |
| " In addition, we looked at benefit and harm comparisons between different dosage regimens for risedronate and between risedronate and other anti-osteoporotic drugs." | 2.82 | Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. ( Hsieh, SC; Liu, W; Peterson, J; Tugwell, P; Wells, GA; Zheng, C, 2022) |
| " A total of 180 women with low bone mineral density were randomly divided into four groups, one in which sodium risedronate was administered with sodium rabeprazole and one in which only risedronate was administered (BP + PPI and BP groups, respectively)." | 2.78 | The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis. ( Itoh, S; Sekino, Y; Shinomiya, K; Takeda, S, 2013) |
| "New hip fractures were significantly less frequent in the risedronate group, suggesting a preventive effect in high-risk patients." | 2.77 | Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women. ( Aoyagi, K; Chiba, K; Doiguchi, Y; Furuichi, I; Hashikawa, T; Motokawa, S; Norimatsu, T; Osaki, M; Shindo, H; Tatsuki, K, 2012) |
| " Administration of risedronate gastric-resistant does not require fasting, and this more convenient dosing administration may explain its improved efficacy." | 1.72 | Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis. ( Alam, A; Boolell, M; Gauthier, G; Palacios, S; Thomasius, F; Vekeman, F, 2022) |
| "Individuals being treated for osteoporosis should be reevaluated for fracture risk routinely, including via patient education about osteoporosis and fractures and monitoring for adverse treatment effects." | 1.56 | Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. ( Adib, G; Adler, RA; Åkesson, KE; Alexander, IM; Amenta, KC; Blank, RD; Brox, WT; Carmody, EE; Chapman-Novakofski, K; Clarke, BL; Cody, KM; Conley, RB; Cooper, C; Crandall, CJ; Dirschl, DR; Eagen, TJ; Elderkin, AL; Fujita, M; Greenspan, SL; Halbout, P; Hochberg, MC; Javaid, M; Jeray, KJ; Kearns, AE; Khosla, S; Kiel, DP; King, T; Koinis, TF; Koontz, JS; Kužma, M; Lindsey, C; Lorentzon, M; Lyritis, GP; Michaud, LB; Miciano, A; Morin, SN; Mujahid, N; Napoli, N; Olenginski, TP; Puzas, JE; Rizou, S; Rosen, CJ; Saag, K; Thompson, E; Tosi, LL; Tracer, H, 2020) |
| "The use of gastro-resistant risedronate, a convenient dosing regimen for oral bisphosphonate therapy, seems a cost-effective strategy compared with weekly alendronate, generic risedronate, and no treatment for the treatment of postmenopausal women with osteoporosis in France." | 1.51 | Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France. ( Hiligsmann, M; Reginster, JY, 2019) |
| "We observed three cohorts of women aged 65 years and older who initiated once-a-week dosing of bisphosphonate therapy; (1) patients adherent to alendronate (n = 21,615), (2) patients adherent to risedronate (n = 12,215), or (3) patients filling only a single bisphosphonate prescription (n = 5,390) as a referent population." | 1.39 | Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy. ( Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB, 2013) |
| " We did not find evidence for a reversal of fracture protection with long-term use of bisphosphonates." | 1.38 | Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases. ( Abrahamsen, B; Pazianas, M; Russell, RG; Wang, Y, 2012) |
| "Osteoporotic fractures are associated with premature mortality." | 1.37 | Osteoporosis medication and reduced mortality risk in elderly women and men. ( Bliuc, D; Center, JR; Eisman, JA; Nguyen, ND; Nguyen, TV, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.67) | 29.6817 |
| 2010's | 48 (80.00) | 24.3611 |
| 2020's | 11 (18.33) | 2.80 |
| Authors | Studies |
|---|---|
| Thomasius, F | 1 |
| Palacios, S | 1 |
| Alam, A | 1 |
| Boolell, M | 1 |
| Vekeman, F | 1 |
| Gauthier, G | 1 |
| Ke, CH | 1 |
| Li, HY | 1 |
| Yang, D | 1 |
| Ying, H | 1 |
| Xu, J | 1 |
| Wang, J | 1 |
| Zhu, HW | 1 |
| Wang, L | 1 |
| Goeree, R | 1 |
| Burke, N | 1 |
| Jobin, M | 1 |
| Brown, JP | 2 |
| Lawrence, D | 1 |
| Stollenwerk, B | 1 |
| Willems, D | 1 |
| Johnson, B | 1 |
| Wells, GA | 1 |
| Hsieh, SC | 1 |
| Zheng, C | 1 |
| Peterson, J | 1 |
| Tugwell, P | 1 |
| Liu, W | 1 |
| Hsu, YH | 1 |
| Li, CC | 1 |
| Liang, FW | 1 |
| Peng, ZY | 1 |
| Chang, YF | 1 |
| Hsu, JC | 1 |
| Ou, HT | 1 |
| Wu, CH | 1 |
| McConnell, M | 1 |
| Shieh, A | 1 |
| Mendes, D | 1 |
| Penedones, A | 1 |
| Alves, C | 1 |
| Oliveira, T | 1 |
| Donato, A | 1 |
| Batel-Marques, F | 1 |
| Gates, M | 1 |
| Pillay, J | 1 |
| Nuspl, M | 1 |
| Wingert, A | 1 |
| Vandermeer, B | 1 |
| Hartling, L | 1 |
| Conley, RB | 1 |
| Adib, G | 1 |
| Adler, RA | 1 |
| Åkesson, KE | 1 |
| Alexander, IM | 1 |
| Amenta, KC | 1 |
| Blank, RD | 1 |
| Brox, WT | 1 |
| Carmody, EE | 1 |
| Chapman-Novakofski, K | 1 |
| Clarke, BL | 1 |
| Cody, KM | 1 |
| Cooper, C | 1 |
| Crandall, CJ | 1 |
| Dirschl, DR | 1 |
| Eagen, TJ | 1 |
| Elderkin, AL | 1 |
| Fujita, M | 1 |
| Greenspan, SL | 3 |
| Halbout, P | 1 |
| Hochberg, MC | 1 |
| Javaid, M | 1 |
| Jeray, KJ | 1 |
| Kearns, AE | 1 |
| King, T | 1 |
| Koinis, TF | 1 |
| Koontz, JS | 1 |
| Kužma, M | 1 |
| Lindsey, C | 1 |
| Lorentzon, M | 1 |
| Lyritis, GP | 1 |
| Michaud, LB | 1 |
| Miciano, A | 1 |
| Morin, SN | 1 |
| Mujahid, N | 1 |
| Napoli, N | 1 |
| Olenginski, TP | 1 |
| Puzas, JE | 1 |
| Rizou, S | 1 |
| Rosen, CJ | 1 |
| Saag, K | 1 |
| Thompson, E | 1 |
| Tosi, LL | 1 |
| Tracer, H | 1 |
| Khosla, S | 1 |
| Kiel, DP | 1 |
| Kendler, DL | 4 |
| Marin, F | 4 |
| Geusens, P | 7 |
| López-Romero, P | 4 |
| Lespessailles, E | 4 |
| Body, JJ | 4 |
| Minisola, S | 5 |
| Shi, L | 1 |
| Min, N | 1 |
| Wang, F | 1 |
| Xue, QY | 1 |
| Zerbini, CAF | 3 |
| Möricke, R | 2 |
| Casado, E | 2 |
| Fahrleitner-Pammer, A | 3 |
| Stepan, JJ | 2 |
| Albert, SG | 1 |
| Reddy, S | 1 |
| Karlsson, L | 1 |
| Mesterton, J | 1 |
| Tepie, MF | 1 |
| Intorcia, M | 1 |
| Overbeek, J | 1 |
| Ström, O | 5 |
| Russo, LA | 2 |
| Zikan, V | 1 |
| Bagur, A | 2 |
| Malouf-Sierra, J | 1 |
| Lakatos, P | 2 |
| Kumagai, K | 1 |
| Harigane, K | 1 |
| Kusayama, Y | 1 |
| Tezuka, T | 1 |
| Choe, H | 1 |
| Inaba, Y | 1 |
| Saito, T | 1 |
| Saag, KG | 3 |
| Wagman, RB | 2 |
| Adachi, JD | 4 |
| Messina, OD | 2 |
| Emkey, R | 2 |
| Chapurlat, R | 1 |
| Wang, A | 1 |
| Pannacciulli, N | 2 |
| Lems, WF | 2 |
| Lee, DR | 1 |
| Lee, J | 2 |
| Bliuc, D | 2 |
| Tran, T | 1 |
| van Geel, T | 1 |
| Berger, C | 1 |
| van den Bergh, J | 1 |
| Eisman, JA | 3 |
| Goltzman, D | 1 |
| Hanley, DA | 1 |
| Josse, RG | 1 |
| Kaiser, S | 1 |
| Kovacs, CS | 1 |
| Langsetmo, L | 1 |
| Prior, JC | 1 |
| Nguyen, TV | 2 |
| Center, JR | 2 |
| Moericke, R | 1 |
| Hiligsmann, M | 1 |
| Reginster, JY | 1 |
| Morales-Torres, J | 1 |
| Butler, PW | 1 |
| Yin, X | 1 |
| Von Schacht, E | 1 |
| Dambacher, MA | 1 |
| Ringe, JD | 3 |
| Dukas, L | 1 |
| Lindsay, R | 2 |
| Watts, NB | 1 |
| Lange, JL | 3 |
| Delmas, PD | 1 |
| Silverman, SL | 2 |
| Anitha, D | 1 |
| Kim, KJ | 1 |
| Lim, SK | 1 |
| Lee, T | 1 |
| Cairoli, E | 1 |
| Eller-Vainicher, C | 1 |
| Ulivieri, FM | 1 |
| Zhukouskaya, VV | 1 |
| Palmieri, S | 1 |
| Morelli, V | 1 |
| Beck-Peccoz, P | 1 |
| Chiodini, I | 1 |
| Roux, C | 2 |
| Ho, PR | 1 |
| Bolognese, MA | 1 |
| Hall, J | 1 |
| Bone, HG | 1 |
| Bonnick, S | 1 |
| van den Bergh, JP | 1 |
| Ferreira, I | 1 |
| Dakin, P | 1 |
| Recknor, C | 1 |
| Messori, A | 1 |
| Fadda, V | 1 |
| Maratea, D | 1 |
| Trippoli, S | 1 |
| Marinai, C | 1 |
| Pepe, J | 1 |
| Isidori, AM | 1 |
| Falciano, M | 1 |
| Iaiani, G | 1 |
| Salotti, A | 1 |
| Diacinti, D | 1 |
| Del Fiacco, R | 1 |
| Sbardella, E | 1 |
| Cipriani, C | 1 |
| Piemonte, S | 1 |
| Raimo, O | 1 |
| Biondi, P | 1 |
| Biamonte, F | 1 |
| Lenzi, A | 1 |
| Landfeldt, E | 1 |
| Garellick, G | 1 |
| Reid, IR | 1 |
| Schilcher, J | 1 |
| Koeppen, V | 1 |
| Aspenberg, P | 1 |
| Michaëlsson, K | 1 |
| Koh, JH | 1 |
| Myong, JP | 1 |
| Jung, SM | 1 |
| Kwok, SK | 1 |
| Park, SH | 1 |
| Ju, JH | 1 |
| Ebina, K | 1 |
| Noguchi, T | 1 |
| Hirao, M | 1 |
| Hashimoto, J | 1 |
| Kaneshiro, S | 1 |
| Yukioka, M | 1 |
| Yoshikawa, H | 1 |
| Xu, LH | 1 |
| Adams-Huet, B | 1 |
| Poindexter, JR | 1 |
| Maalouf, NM | 1 |
| Marques, A | 1 |
| Lourenço, Ó | 1 |
| Ortsäter, G | 1 |
| Borgström, F | 2 |
| Kanis, JA | 4 |
| da Silva, JA | 1 |
| Bilek, LD | 1 |
| Waltman, NL | 1 |
| Lappe, JM | 1 |
| Kupzyk, KA | 1 |
| Mack, LR | 1 |
| Cullen, DM | 1 |
| Berg, K | 1 |
| Langel, M | 1 |
| Meisinger, M | 1 |
| Portelli-Trinidad, A | 1 |
| Lang, M | 1 |
| Davis, S | 1 |
| Martyn-St James, M | 1 |
| Sanderson, J | 1 |
| Stevens, J | 1 |
| Goka, E | 1 |
| Rawdin, A | 1 |
| Sadler, S | 1 |
| Wong, R | 1 |
| Campbell, F | 1 |
| Stevenson, M | 1 |
| Strong, M | 1 |
| Selby, P | 1 |
| Gittoes, N | 1 |
| Mawatari, T | 1 |
| Muraoka, R | 1 |
| Iwamoto, Y | 1 |
| Bell, JM | 1 |
| Shields, MD | 1 |
| Watters, J | 1 |
| Hamilton, A | 1 |
| Beringer, T | 1 |
| Elliott, M | 1 |
| Quinlivan, R | 1 |
| Tirupathi, S | 1 |
| Blackwood, B | 1 |
| Imai, T | 1 |
| Tanaka, S | 1 |
| Kawakami, K | 1 |
| Miyazaki, T | 1 |
| Hagino, H | 1 |
| Shiraki, M | 1 |
| Nayak, S | 1 |
| Kennedy, CC | 1 |
| Papaioannou, A | 2 |
| Ioannidis, G | 1 |
| Leslie, WD | 1 |
| Walker, V | 1 |
| Coelho, J | 1 |
| Johansson, H | 1 |
| Oden, A | 1 |
| McCloskey, EV | 1 |
| Abelson, A | 2 |
| Gold, DT | 2 |
| Thomas, T | 2 |
| Guerra-García, MM | 1 |
| Rodríguez-Fernández, JB | 1 |
| Puga-Sarmiento, E | 1 |
| Charle-Crespo, MÁ | 1 |
| Gomes-Carvalho, CS | 1 |
| Prejigueiro-Santás, A | 1 |
| Duque, G | 1 |
| Li, W | 1 |
| Adams, M | 1 |
| Xu, S | 1 |
| Phipps, R | 1 |
| Jönsson, B | 2 |
| Siris, ES | 1 |
| Tosteson, A | 1 |
| Nguyen, ND | 1 |
| Goldstein, JL | 1 |
| Zhou, X | 1 |
| Klemes, A | 1 |
| Osaki, M | 1 |
| Tatsuki, K | 1 |
| Hashikawa, T | 1 |
| Norimatsu, T | 1 |
| Chiba, K | 1 |
| Motokawa, S | 1 |
| Furuichi, I | 1 |
| Doiguchi, Y | 1 |
| Aoyagi, K | 1 |
| Shindo, H | 1 |
| Cheen, MH | 1 |
| Kong, MC | 1 |
| Zhang, RF | 1 |
| Tee, FM | 1 |
| Chandran, M | 1 |
| Hadji, P | 1 |
| Zanchetta, JR | 1 |
| Russo, L | 1 |
| Recknor, CP | 1 |
| McKiernan, FE | 1 |
| Alam, J | 1 |
| Burge, RT | 1 |
| Krege, JH | 1 |
| Lakshmanan, MC | 1 |
| Masica, DN | 1 |
| Mitlak, BH | 1 |
| Stock, JL | 1 |
| Sergi, G | 1 |
| Pintore, G | 1 |
| Falci, C | 1 |
| Veronese, N | 1 |
| Berton, L | 1 |
| Perissinotto, E | 1 |
| Basso, U | 1 |
| Brunello, A | 1 |
| Monfardini, S | 1 |
| Manzato, E | 1 |
| Coin, A | 1 |
| Pazianas, M | 1 |
| Abrahamsen, B | 1 |
| Wang, Y | 1 |
| Russell, RG | 1 |
| Kim, TY | 1 |
| Ha, YC | 1 |
| Kang, BJ | 1 |
| Lee, YK | 1 |
| Koo, KH | 1 |
| Horlait, S | 1 |
| Atlan, P | 1 |
| Itoh, S | 1 |
| Sekino, Y | 1 |
| Shinomiya, K | 1 |
| Takeda, S | 1 |
| Ohtori, S | 1 |
| Inoue, G | 1 |
| Orita, S | 1 |
| Yamauchi, K | 1 |
| Eguchi, Y | 1 |
| Ochiai, N | 1 |
| Kishida, S | 1 |
| Kuniyoshi, K | 1 |
| Aoki, Y | 1 |
| Nakamura, J | 1 |
| Ishikawa, T | 1 |
| Miyagi, M | 1 |
| Kamoda, H | 1 |
| Suzuki, M | 1 |
| Kubota, G | 1 |
| Sakuma, Y | 1 |
| Oikawa, Y | 1 |
| Inage, K | 1 |
| Sainoh, T | 1 |
| Takaso, M | 1 |
| Toyone, T | 1 |
| Takahashi, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Teriparatide and Risedronate in the Treatment of Patients With Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures[NCT01709110] | Phase 4 | 1,366 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Efficacy of Denosumab and Zoledronic Acid in the Treatment of Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density: a Prospective Controlled Trial[NCT04034199] | Phase 3 | 40 participants (Anticipated) | Interventional | 2019-08-15 | Not yet recruiting | ||
| A Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Denosumab Compared With Risedronate in Glucocorticoid-treated Individuals[NCT01575873] | Phase 3 | 795 participants (Actual) | Interventional | 2012-03-28 | Completed | ||
| Risedronate With High-dose Vitamin D Resolves Hyperparathyroidism and Hypovitaminosis D But Not Osteoporosis in Mexican Postmenopausal Patients[NCT05346419] | 33 participants (Actual) | Interventional | 2021-07-01 | Completed | |||
| STOP Vertigo: Supplementation of Vitamin D for Termination of Recurrences From Benign Paroxysmal Positional Vertigo[NCT05863949] | 860 participants (Anticipated) | Interventional | 2023-07-31 | Not yet recruiting | |||
| Randomized Control Trial of Bone Loading Exercises Versus Risedronate on Bone Health in Post-Menopausal Women[NCT02186600] | Phase 3 | 276 participants (Actual) | Interventional | 2015-02-01 | Completed | ||
| Resolution of Hyperparathyroidism With High-dose Vitamin D Improves Osteoporosis in Multi-treated Postmenopausal Women[NCT05347082] | 47 participants (Actual) | Interventional | 2021-04-29 | Completed | |||
| A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis Every 6 Months)[NCT00089791] | Phase 3 | 7,808 participants (Actual) | Interventional | 2004-08-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A major non-vertebral fracture is a fracture at any of the following non-vertebral sites hip, radius, humerus, ribs, pelvis, tibia and femur. Non-vertebral fractures were determined by direct questioning at each visit, and confirmed by the site investigators by x-ray, radiology or surgical report. Fractures resulting from a severe trauma such as a traffic collision, a beating, or having been struck by a falling or moving. (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 18 |
| Risedronate | 31 |
Vertebrae were graded as moderate (SQ2), or severe (SQ3) fractures, based on ~25 to 40% (moderate) or ~40% or more (severe) decrease in anterior, central, or posterior vertebral height (T4 through L4). (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 26 |
| Risedronate | 63 |
(NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 2 |
| Risedronate | 12 |
"The incidence of new vertebral fractures was assessed by quantitative vertebral morphometry measurements (QM) with qualitative visual semiquantitative grading (SQ) confirmation.~A new vertebral fracture was diagnosed in a vertebra that was non-fractured at the baseline radiological examination. It was defined as a loss of vertebral body height of at least 20% and 4 mm from the baseline radiograph by vertebral QM, based upon placement of six points by a trained, central reader. Any fractures identified by QM were confirmed using SQ: if the vertebral body also had an increase of one or more severity grade, it was considered an incident vertebral fracture." (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 28 |
| Risedronate | 64 |
A non-vertebral fracture is a fracture at any of the following non-vertebral sites: clavicle, scapula, ribs, sternum, sacrum, coccyx, humerus, radius, ulna, carpus, pelvis, hip, femur, patella, tibia, fibula, ankle, calcaneus, tarsus, and metatarsal. Non-vertebral fractures were determined by direct questioning at each visit, and confirmed by the site investigators by x-ray, radiology or surgical report. Fractures resulting from a severe trauma such as a traffic collision, a beating, or having been struck by a falling or moving object were not considered fragility fractures but traumatic fractures. (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 25 |
| Risedronate | 38 |
"A clinical vertebral fracture was defined as a new or worsening vertebral fracture, confirmed by radiography, that was associated with signs and symptoms highly suggestive of a vertebral fracture.~All non-vertebral fractures that occurred and were diagnosed between visits required the confirmation by the site investigators after evaluating the original x-ray film(s), the radiology or surgical report. For clinical vertebral fractures, the final confirmation of the diagnosis required the centralized evaluation by a trained, independent reader." (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 30 |
| Risedronate | 61 |
Traumatic fractures were considered if resulting from a severe trauma such as a traffic collision, a beating, or having been struck by a falling or moving object. (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 40 |
| Risedronate | 57 |
Worsening of a pre-existing fracture was considered if the decrease in vertebral height was at least one severity grade in the semi-quantitative assessment, confirmed by a trained central reader, where vertebrae were graded as normal (SQ0) or as with mild (SQ1), moderate (SQ2), or severe (SQ3) fractures, defined as ~20 to 25% (mild), ~25 to 40% (moderate) or ~40% or more (severe) decrease in anterior, central, or posterior vertebral height (T4 to L4). (NCT01709110)
Timeframe: Baseline through 24 Months
| Intervention | Participants (with at least one event) (Number) |
|---|---|
| Teriparatide | 31 |
| Risedronate | 69 |
Participants rated the worst back pain during the 24 hours preceding the visit at baseline and each post-baseline visit. An 11-point numerical back pain rating scale (rated from 0 = no back pain to 10 = worst possible back pain) was used. (NCT01709110)
Timeframe: Baseline, 24 Months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 24 Months | |
| Risedronate | 4.5 | 3.4 |
| Teriparatide | 4.5 | 3.4 |
(NCT01709110)
Timeframe: Baseline, 24 Months
| Intervention | Centimeter (cm) (Mean) | |
|---|---|---|
| Baseline | 24 Months | |
| Risedronate | 155.0 | 154.5 |
| Teriparatide | 154.7 | 154.3 |
The EQ-5D-5L is a generic, multidimensional, health-related, quality-of-life instrument completed on five dimensions to measure health-related quality of life. The profile allowed participants to rate their health state in five health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a five level scale (no problems, slight problems, moderate problems, severe problems, and unable to/extreme problems). The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.59 to 1.0. A higher score indicates better health state. (NCT01709110)
Timeframe: Baseline, 24 Months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 24 Months | |
| Risedronate | 0.62 | 0.68 |
| Teriparatide | 0.59 | 0.65 |
The EQ-5D-5L is a generic, multidimensional, health-related, quality-of-life instrument completed on five dimensions to measure health-related quality of life. The profile allowed participants to rate their health state in five health domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression using a five level scale (no problems, slight problems, moderate problems, severe problems, and unable to/extreme problems). The responses are used to derive the health state index scores using the United States (US) cross walk algorithm, with scores ranging from -0.11 to 1.0. A higher score indicates better health state. (NCT01709110)
Timeframe: Baseline, 24 Months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 24 Months | |
| Risedronate | 0.72 | 0.76 |
| Teriparatide | 0.70 | 0.74 |
Bone mineral density at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA). (NCT01575873)
Timeframe: Baseline and month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Risedronate: Glucocorticoid-initiating | 0.8 |
| Denosumab: Glucocorticoid-initiating | 3.8 |
| Risedronate: Glucocorticoid-continuing | 2.3 |
| Denosumab: Glucocorticoid-continuing | 4.4 |
Bone mineral density at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA). (NCT01575873)
Timeframe: Baseline and month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Risedronate: Glucocorticoid-initiating | 0.8 |
| Denosumab: Glucocorticoid-initiating | 3.8 |
| Risedronate: Glucocorticoid-continuing | 2.3 |
| Denosumab: Glucocorticoid-continuing | 4.4 |
Bone mineral density at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA). (NCT01575873)
Timeframe: Baseline and month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Risedronate: Glucocorticoid-initiating | 1.7 |
| Denosumab: Glucocorticoid-initiating | 6.2 |
| Risedronate: Glucocorticoid-continuing | 3.2 |
| Denosumab: Glucocorticoid-continuing | 6.4 |
Bone mineral density at the total hip was measured by dual-energy x-ray absorptiometry (DXA). (NCT01575873)
Timeframe: Baseline and month 12
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Risedronate: Glucocorticoid-initiating | 0.2 |
| Denosumab: Glucocorticoid-initiating | 1.7 |
| Risedronate: Glucocorticoid-continuing | 0.6 |
| Denosumab: Glucocorticoid-continuing | 2.1 |
Bone mineral density at the total hip was measured by dual-energy x-ray absorptiometry (DXA). (NCT01575873)
Timeframe: Baseline and month 24
| Intervention | percent change (Least Squares Mean) |
|---|---|
| Risedronate: Glucocorticoid-initiating | -0.0 |
| Denosumab: Glucocorticoid-initiating | 3.1 |
| Risedronate: Glucocorticoid-continuing | 0.5 |
| Denosumab: Glucocorticoid-continuing | 2.9 |
Bone mineral density is the gold standard for diagnosis of low bone mass and osteoporosis and will be measured at the spine using Dual Energy X-ray Absorptiometry (DXA). (NCT02186600)
Timeframe: Baseline,6, and 12 months
| Intervention | g/cm^2 (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 0.889 | .887 | 0.885 |
| Exercise | 0.886 | .878 | 0.885 |
| Risedronate | 0.892 | .907 | 0.911 |
"Change in Bone Strength Index (BSI) of the distal tibia based on randomization to Control, Risedronate, or Exercise group.~BSI (mg2/mm4) at the 4% tibial site will be measured using peripheral quantitative computed tomography (pQCT)." (NCT02186600)
Timeframe: Baseline, 6, and 12 months
| Intervention | mg^2/mm^4 (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 2098.7 | 2105.89 | 2107.2 |
| Exercise | 2001 | 1987.42 | 2009.2 |
| Risedronate | 1993.3 | 1997.32 | 2014.2 |
Bone turnover is the process of removing old bone (resorption by osteoclasts) and replacing it with new bone (formation by osteoblasts). Menopause results in a brief period (~5 years) of accelerated turnover with resorption far exceeding formation. In this study, resorption will be measured by Serum NTx. (NCT02186600)
Timeframe: Baseline, 6, 12 months
| Intervention | nanoMolar Bone Collagen Equivalents/L (Mean) | ||
|---|---|---|---|
| Baseline | 6 Months | 12 Months | |
| Control | 13.99 | 12.16 | 12.36 |
| Exercise | 15.03 | 13.36 | 13.92 |
| Risedronate | 14.31 | 10.30 | 11.42 |
Hip fractures are a subset of nonvertebral fractures including femur neck, femur intertrochanter, and femur subtrochanter. (NCT00089791)
Timeframe: 36 months
| Intervention | Participants (Number) |
|---|---|
| Placebo | 43 |
| Denosumab 60 mg Q6M | 26 |
A new vertebral fracture, assessed by lateral spine X-ray using Genant semiquantitative scoring method, was identified as an ≥ 1 grade increase from the Baseline grade of 0 in any vertebra from T4 to L4. New vertebral fractures included morphometric vertebral fractures (assessed at scheduled visits and not associated with signs or symptoms [or both] indicative of a fracture) and clinical vertebral fractures (assessed at either a scheduled or unscheduled visit and associated with any signs and/or symptoms indicative of a fracture, excluding any fracture associated with high trauma severity or a pathologic fracture). (NCT00089791)
Timeframe: 36 months
| Intervention | Participants (Number) |
|---|---|
| Placebo | 264 |
| Denosumab 60 mg Q6M | 86 |
Nonvertebral fractures (osteoporotic) were those occurring on study excluding those of the vertebrae (cervical, thoracic, and lumbar), skull, facial, mandible, metacarpus, finger phalanges, and toe phalanges. Fractures associated with high trauma severity (fractures that were the result of a fall from higher than the height of a stool, chair, first rung on a ladder or equivalent (> 20 inches) or was the result of severe trauma other than a fall) and pathologic fractures were excluded from this category. Nonvertebral fractures were required to be confirmed either by radiographs or other diagnostic images such as computerized tomography (CT) or magnetic resonance imaging (MRI), or by documentation in a radiology report, surgical report, or discharge summary. (NCT00089791)
Timeframe: 36 months
| Intervention | Participants (Number) |
|---|---|
| Placebo | 293 |
| Denosumab 60 mg Q6M | 238 |
15 reviews available for risedronic acid and Osteoporotic Fractures
| Article | Year |
|---|---|
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Topics: Aged; Female; Hip Fractures; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractu | 2022 |
Reduced All-Cause Mortality With Bisphosphonates Among Post-Fracture Osteoporosis Patients: A Nationwide Study and Systematic Review.
Topics: Diphosphonates; Humans; Ibandronic Acid; Osteoporosis; Osteoporotic Fractures; Risedronic Acid; Zole | 2022 |
Polypharmacy in Osteoporosis Treatment.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Bone; Hum | 2022 |
Ibandronate in the Prevention of Vertebral and Nonvertebral Osteoporotic Fractures: A Systematic Review of Experimental and Observational Studies.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Obse | 2023 |
Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Topics: Adult; Alendronate; Canada; Denosumab; Diphosphonates; Female; Hip Fractures; Humans; Male; Middle A | 2023 |
Bisphosphonates for Secondary Prevention of Osteoporotic Fractures: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Topics: Aged; Alendronate; Bayes Theorem; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; | 2019 |
CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Topics: Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Diphosphonates; Dru | 2017 |
[Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence].
Topics: Aged; Alendronate; Animals; Bone Density; Disease Models, Animal; Drug Combinations; Drug Interactio | 2012 |
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bis
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bone Densit | 2014 |
Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosp | 2014 |
A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
Topics: Alendronate; Bone Density Conservation Agents; Cost of Illness; Cost-Benefit Analysis; Diphosphonate | 2016 |
Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials.
Topics: Adult; Age Factors; Aged; Bone Density; Bone Density Conservation Agents; Clinical Trials, Phase III | 2017 |
Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.
Topics: Adolescent; Adrenal Cortex Hormones; Bone Density; Bone Density Conservation Agents; Calcium; Child; | 2017 |
Osteoporosis Treatment Efficacy for Men: A Systematic Review and Meta-Analysis.
Topics: Alendronate; Bone Density Conservation Agents; Calcitonin; Denosumab; Humans; Male; Osteoporosis; Os | 2017 |
Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Fem | 2012 |
13 trials available for risedronic acid and Osteoporotic Fractures
| Article | Year |
|---|---|
Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.
Topics: Bone Density; Bone Density Conservation Agents; Female; Humans; Osteoporosis, Postmenopausal; Osteop | 2020 |
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
Topics: Aged; Aged, 80 and over; Americas; Bone Density; Bone Density Conservation Agents; Double-Blind Meth | 2018 |
Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
Topics: Administration, Oral; Aged; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; B | 2018 |
Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.
Topics: Aged; Bone Density; Denosumab; Double-Blind Method; Female; Glucocorticoids; Humans; Male; Middle Ag | 2018 |
Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.
Topics: Aged; Bone Density; Denosumab; Double-Blind Method; Female; Glucocorticoids; Humans; Male; Middle Ag | 2018 |
Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.
Topics: Aged; Bone Density; Denosumab; Double-Blind Method; Female; Glucocorticoids; Humans; Male; Middle Ag | 2018 |
Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.
Topics: Aged; Bone Density; Denosumab; Double-Blind Method; Female; Glucocorticoids; Humans; Male; Middle Ag | 2018 |
Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.
Topics: Aged; Bone Density Conservation Agents; Double-Blind Method; Female; Humans; Middle Aged; Osteoporos | 2019 |
Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
Topics: Absorptiometry, Photon; Aged; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Colla | 2019 |
Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Bone Density Conservation Agents; Drug Therapy, | 2017 |
Effects of risedronate on bone marrow adipocytes in postmenopausal women.
Topics: Adipocytes; Adipogenesis; Aged; Bone Density Conservation Agents; Bone Marrow; Bone Marrow Cells; Et | 2011 |
Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Epidemiologic Methods; Etid | 2012 |
The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
Topics: Aged; Back Pain; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid | 2012 |
Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures?
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic A | 2012 |
The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis.
Topics: Bone Density Conservation Agents; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Middle | 2013 |
Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Screws; Etidronic Acid | 2013 |
32 other studies available for risedronic acid and Osteoporotic Fractures
| Article | Year |
|---|---|
Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis.
Topics: Alendronate; Bone Density Conservation Agents; Data Analysis; Diphosphonates; Etidronic Acid; Female | 2022 |
Dynamic Effects of the Third Generation Bisphosphonate of Risedronate on Rat Osteoporotic Fractures for Clinical Usage Guidance.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Femoral Fractures; | 2021 |
Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada.
Topics: Alendronate; Antibodies, Monoclonal; Bone Density Conservation Agents; Cost-Benefit Analysis; Female | 2022 |
Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition.
Topics: Alendronate; Bone Density Conservation Agents; Consensus; Diphosphonates; Humans; Osteoporosis; Oste | 2020 |
Efficacy of teriparatide compared with risedronate on FRAX
Topics: Aged; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Female; Humans; Osteoporo | 2020 |
Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Etidronic | 2017 |
Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Databases, Factual; Drug Administratio | 2019 |
Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Canada; Diphosphonates; Etidronic Acid; Female; | 2019 |
Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-B | 2019 |
Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; E | 2013 |
Implications of local osteoporosis on the efficacy of anti-resorptive drug treatment: a 3-year follow-up finite element study in risedronate-treated women.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Femur Neck; Finite Ele | 2013 |
Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Bone | 2014 |
Effect of risedronate in osteoporotic HIV males, according to gonadal status: a pilot study.
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Chol | 2014 |
Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA).
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Comorb | 2015 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; | 2015 |
Risk of atypical femoral fracture during and after bisphosphonate use.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Cohort | 2015 |
Atypical Femoral Fracture in Rheumatoid Arthritis Patients Treated With Bisphosphonates: A Nested Case-Control Study.
Topics: Absorptiometry, Photon; Aged; Alendronate; Arthritis, Rheumatoid; Bone Density; Bone Density Conserv | 2016 |
Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Biomarke | 2016 |
Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
Topics: Aged; Alendronate; Body Weight; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fema | 2016 |
Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal.
Topics: Aged; Alendronate; Algorithms; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analys | 2016 |
Protocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal women.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Exercise; Female; Humans; Mid | 2016 |
Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers?
Topics: Aged; Bone Density Conservation Agents; Canada; Decision Making; Epidemiologic Methods; Etidronic Ac | 2009 |
The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.
Topics: Age Factors; Aged; Aged, 80 and over; Algorithms; Bone Density Conservation Agents; Cost-Benefit Ana | 2010 |
Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
Topics: Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Epidemiologic Meth | 2010 |
[Incidence of hip fractures due to osteoporosis in relation to the prescription of drugs for their prevention and treatment in Galicia, Spain].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drug Prescriptions; Etidronic Acid; Female; Hip | 2011 |
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bon | 2011 |
Osteoporosis medication and reduced mortality risk in elderly women and men.
Topics: Aged; Aged, 80 and over; Alendronate; Algorithms; Bone Density Conservation Agents; Cohort Studies; | 2011 |
Adherence to osteoporosis medications amongst Singaporean patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosph | 2012 |
Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone De | 2012 |
Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
Topics: Administration, Oral; Aged; Alendronate; Cohort Studies; Diphosphonates; Drug Administration Schedul | 2012 |
Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic | 2013 |
Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Algorithms; Antibodies, Monoclonal, Humanized; Bone Density Co | 2013 |